Zühlke Ventures AG

Zühlke Ventures AG is a venture capital firm that operates as a subsidiary of Zühlke Technology Group AG, focusing on financing early-stage start-ups and providing growth capital primarily in the healthtech, technology, and medical device sectors. The company invests mainly in Switzerland and the United States, with additional interests in German-speaking Europe and Great Britain. Zühlke Ventures typically commits between CHF0.5 million and CHF1 million to companies with an enterprise value ranging from CHF0.5 million to CHF5 million, holding minority stakes in these investments. The firm emphasizes a co-entrepreneurial approach, utilizing its own capital for investments and aiming for exits within a timeframe of six to ten years, often through trade sales. Established on January 11, 2011, Zühlke Ventures AG is headquartered in Zurich, Switzerland, and maintains an office in Porto, Portugal.

12 past transactions

Indivi

Seed Round in 2022
Indivi is a Medical Device Software Manufacturer that is dedicated to finding solutions in clinical research and patient monitoring through innovative digital technologies. With novel, validated and patented Digital Biomarkers, we aim at measuring – with unprecedented sensitivity – changes in motor and cognitive functions in patients with neurological disorders. These novel biomarkers will establish a new standard for both pharmacological research and clinical practice.

Evismo

Seed Round in 2021
Evismo AG, founded in 2018 and headquartered in Zurich, Switzerland, specializes in web-based remote vital signs monitoring services, particularly focusing on cardiac health. The company offers CardioFlex, an advanced online ECG service that aids healthcare professionals, including general practitioners, cardiologists, clinics, and hospitals, in diagnosing and managing conditions such as cardiac arrhythmias, sleep apnea, and stress. By providing accessible ECG data, Evismo integrates patient-centered medical care into daily life, enabling timely diagnoses and enhancing treatment options. The company's approach emphasizes cost-effective solutions that improve overall patient outcomes in diagnostics, prevention, and therapy.

Flow Neuroscience

Series A in 2021
Flow Neuroscience AB is a healthcare company based in Malmö, Sweden, focused on developing innovative treatment solutions for depression. Established in 2011, the company creates a wearable device that delivers transcranial direct current stimulation (tDCS) to the forehead, targeting the left frontal lobe, an area often associated with reduced activity in individuals suffering from major depressive disorder (MDD). This headset is complemented by a personalized mobile application designed to encourage users to adopt healthier daily routines, such as improved sleep patterns and increased physical activity. By combining brain stimulation with behavioral therapy, Flow Neuroscience aims to provide a medication-free treatment option that is accessible and affordable, challenging the traditional pharmaceutical approaches to depression. The company aspires to make these effective treatments widely available, moving beyond the confines of specialized clinics.

Koya Medical

Venture Round in 2020
Koya Medical, Inc., founded in 2018 and based in Oakland, California, specializes in developing innovative therapeutic devices aimed at treating cancer-related chronic lymphedema and various venous diseases. The company focuses on creating wearable technology that delivers active compression therapy, which is designed to enhance movement and mobility for patients. Koya Medical's approach offers a personalized alternative to traditional compression methods, utilizing a sensor-based closed-loop system to provide tailored compression patterns. This technology addresses the needs of patients suffering from conditions such as lymphedema, chronic edema, and chronic venous insufficiency, thereby improving their quality of care and overall treatment outcomes.

Lunaphore

Series A in 2017
Lunaphore specializes in tumor analysis through innovative microfluidic chip technology, which allows for rapid and precise assays that surpass traditional methods. The company's platform facilitates the extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology with a user-friendly interface. This technology aids researchers in immunology, immuno-oncology, and neurology by identifying clinically relevant biomarker signatures, which support the development of diagnostic tools and streamline clinical trials. By improving the efficiency of cancer diagnostics and enhancing the accuracy of results, Lunaphore ultimately aims to contribute to better patient outcomes.

Swisstom

Series C in 2014
Swisstom AG, based in Landquart, Switzerland, specializes in the development and manufacturing of innovative medical devices focused on monitoring lung and heart function. Founded in 2009, the company offers advanced solutions such as the Swisstom BB2, designed for monitoring lung function in intensive care unit patients undergoing mechanical ventilation, and the elisa 800VIT, which visualizes ventilation-related complications for direct intervention. Utilizing Electrical Impedance Tomography (EIT), Swisstom's devices provide real-time, non-radiating bedside imaging that enhances patient monitoring and treatment, particularly for those facing acute respiratory distress syndrome. Their products are utilized by healthcare professionals to improve patient outcomes during critical care and anesthesia. As of July 2018, Swisstom AG operates as a subsidiary of SenTec AG.

DSwiss

Venture Round in 2014
DSwiss AG is a prominent provider of secure digital services, catering to individuals and companies globally. Founded in 2008 and headquartered in Zurich, Switzerland, the company specializes in digital vaults for personal documents and passwords, as well as secure technology for document delivery and file sharing tailored for asset managers and banking clients. DSwiss is committed to meeting high security standards for cloud solutions, which has attracted a diverse client portfolio, including numerous banks and insurance firms. The company also offers customized IT services that span project planning, implementation, and development, ensuring comprehensive solutions to meet stringent security requirements.

Distalmotion

Series A in 2013
Distalmotion is a medical device company headquartered in Lausanne, Switzerland, focused on simplifying robotic surgery to enhance patient access to minimally invasive care in general surgery, gynecology, and urology. The company has developed a surgical robot named Dexter, which is designed and manufactured in Switzerland. Dexter merges the advantages of traditional laparoscopy with robotic capabilities, offering an innovative, on-demand approach to surgical procedures. This technology allows healthcare professionals to perform dissection and suturing in the abdominal cavity, streamlining the surgical process while maintaining affordability. Distalmotion aims to set a new standard of care by improving surgical outcomes and accessibility through its advanced robotic solutions.

Leman Micro Devices

Series A in 2013
Leman Micro Devices SA, founded in 2013 and based in Lausanne, Switzerland, specializes in innovative health monitoring technology for smartphones. The company has developed the V-Sensor, a pioneering miniature device that accurately measures five vital signs: blood pressure, blood oxygen (SpO2), respiration rate, pulse rate, and body temperature. This device operates without cuffs or the need for calibration, delivering results on-screen in under one minute through LMD’s e-Checkup app. Launched at CES 2021, the V-Sensor is designed to provide users with a convenient way to monitor their health using smartphones and wearable technology.

Tenon Technology

Series A in 2013
Lower back pain is one of the most common types of back pain in adults and can be debilitating. There are many different diagnoses, but the sacroiliac (SI) joint is involved in more than 15% of cases. The joint connects the hip bones to the spinal column and as a consequence experiences constant strain. Inflammation of the SI joint is correspondingly painful. In chronic cases which are not well controlled by physiotherapy and painkillers, surgical fixation of the joint remains the only option. The market for SI joint fixation is large and is growing disproportionately compared to the back orthopaedic market as a whole
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.